Cortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

Key Points

• Shares of Cortexyme, Inc. (NASDAQ:CRTX) have crossed above their 200-day moving average of $1.37, reaching a high of $1.76 during trading.
• The stock is currently trading at $1.69 with a market cap of approximately $50.96 million and a P/E ratio of -0.57.
• Cortexyme is a clinical-stage biopharmaceutical company developing therapies for Alzheimer's disease and other degenerative diseases, with its lead candidate, atuzaginstat, in Phase II/III trials.

Shares of Cortexyme, Inc. (NASDAQ:CRTX - ) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.37 and traded as high as $1.76. Cortexyme shares last traded at $1.69, with a volume of 166,060 shares traded.

Cortexyme Stock Up 0.6%

The firm has a market cap of $50.96 million, a P/E ratio of -0.57 and a beta of 1.40. The firm's 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.37.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.